Clinical Core

亚利桑那州 ADCC 的临床核心是由六个招募地点（班纳阿尔茨海默研究所、巴罗神经学研究所、亚利桑那州梅奥诊所、​​班纳太阳健康研究所、亚利桑那大学健康科学中心和退伍军人管理局医疗中心）组成的联盟，在全州范围内提供服务区域，作为单一临床核心主任领导下的标准化单位。临床核心保持 目标是 500 名处于衰老-痴呆谱系各个阶段的参与者，其中包括 325 名正常对照、75 名轻度认知障碍 (MCI) 患者和 100 名阿尔茨海默病 (AD) 和其他形式的退行性痴呆患者。这些诊断类别中包含了拉丁裔和美洲原住民群体的定义。临床核心利用我们的多机构诊断共识会议， 集中的数据管理程序，以及与其他每个核心的密切工作关系。所有受试者均接受标准化诊断测试，这些测试： 1) 满足严格的入学标准； 2) 包括人口统计、历史、医学、神经学、精神病学、神经心理学和遗传测量； 3）纳入NACC统一数据集（UDS）； 4) 采用文化敏感的测试程序。 符合入组条件的患者和完成年度随访的患者将在每两周一次的诊断共识会议上进行讨论。所有患者在入境时均接受载脂蛋白 E (APOE) 基因分型，并在所有地点进行年度标准化神经心理学测试。我们会持续跟踪和审查患者参与正在进行的研究项目的资格和参与情况。所有人都可以在大脑中注册 用于临床诊断的神经病理学确认的捐赠计划，但文化敏感的多样性亚群体（拉丁裔和美洲原住民）的成员不需要脑捐赠。纵向研究衰老正常对照的辅助项目也得到 NACC UDS 通过其他资助机制的支持。这些队列提供了独特的机会来研究 AD 不同风险人群的认知正常和 MCI 之间的转变，并利用我们在影像学、基因组学、认知神经科学和其他研究方法方面的优势。为了实现 ADCC 的目标，独立资助项目的主题和数据现在可以作为其他资源 研究人员正在将其用于其他研究，并将使用 UDS 进行前瞻性跟踪。

The Clinical Core of the Arizona ADCC is a consortium of six recruitment sites (Banner Alzheimer Institute, Barrow Neurological Institute, Mayo Clinic Arizona, Banner Sun Health Research Institute, and the University of Arizona Health Sciences Center and VA medical Center) providing catchment areas throughout the state that function as a standardized unit under a single Clinical Core Director. The Clinical Core maintains a target of 500 participants at all stages of the aging-dementia spectrum including 325 normal controls, 75 patients with mild cognitive impairment (MCI), and 100 with Alzheimer's disease (AD) and other forms of degenerative dementia. Embedded within these diagnostic categories are defined Latino and Native American cohorts. The Clinical Core capitalizes on our multi-institutional diagnostic consensus conference, centralized data management program, and close working relationships with each of the other Cores. All subjects undergo standardized diagnostic testing that: 1) fulfills strict entrance criteria; 2) includes demographic, historical, medical, neurological, psychiatric, neuropsychological, and genetic measures; 3) incorporates the NACC Uniform Data Set (UDS); and 4) employs culturally sensitive test procedures. Patients eligible for enrollment and those completing annual follow-up are discussed in a biweekly diagnostic consensus conference. All undergo apolipoprotein E (APOE) genotyping at entry, and an annual standardized neuropsychological battery of tests at all sites. Patient eligibility for and participation in ongoing research projects is tracked and reviewed on an ongoing basis. All are offered enrollment in the Brain Donation Program for neuropathological confirmation of clinical diagnoses, though brain donation is not required of members of culturally sensitive diversity subgroups (Latino and Native Americans). Ancillary programs of longitudinally studied aging normal controls also receive the NACC UDS supported through other funding mechanisms. These cohorts provide unique opportunities to study the transition between cognitive normality and MCI in persons at differential risk for AD and to capitalize on our strengths in maging, genomics, cognitive neuroscience, and other research methods. To address the goals of the ADCC, subjects and data from independently funded projects are now available as a resource to other researchers, being used in other studies, and will be followed prospectively using the UDS.